210 related articles for article (PubMed ID: 31863347)
1. Salt intake in mineralocorticoid receptor antagonist-treated primary aldosteronism: foe or ally?
Fountoulakis S; Papanastasiou L; Voulgaris N; Kounadi T; Markou A; Chrousos GP; Piaditis G
Hormones (Athens); 2020 Jun; 19(2):223-232. PubMed ID: 31863347
[TBL] [Abstract][Full Text] [Related]
2. Hyperkalemia in both surgically and medically treated patients with primary aldosteronism.
Wada N; Shibayama Y; Umakoshi H; Ichijo T; Fujii Y; Kamemura K; Kai T; Sakamoto R; Ogo A; Matsuda Y; Fukuoka T; Tsuiki M; Suzuki T; Naruse M
J Hum Hypertens; 2017 Oct; 31(10):627-632. PubMed ID: 28540931
[TBL] [Abstract][Full Text] [Related]
3. Importance of dietary salt restriction for patients with primary aldosteronism during treatment with mineralocorticoid receptor antagonists: The potential importance of post-treatment plasma renin levels.
Yoshida Y; Fujiki R; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Mori Y; Matsuda N; Noguchi T; Nakama H; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2023 Jan; 46(1):100-107. PubMed ID: 36229529
[TBL] [Abstract][Full Text] [Related]
4. Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.
Yoshida Y; Fujiwara M; Kinoshita M; Sada K; Miyamoto S; Ozeki Y; Iwamoto M; Mori Y; Nagai S; Matsuda N; Noguchi T; Okamoto M; Gotoh K; Masaki T; Shibata H
Hypertens Res; 2024 Jan; 47(1):157-167. PubMed ID: 37717115
[TBL] [Abstract][Full Text] [Related]
5. Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study.
Rossi GP; Ceolotto G; Rossitto G; Maiolino G; Cesari M; Seccia TM
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32067030
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the diagnosis and treatment of primary aldosteronism.
Yoshida Y; Shibata H
Hypertens Res; 2023 Jul; 46(7):1738-1744. PubMed ID: 37198444
[TBL] [Abstract][Full Text] [Related]
7. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
Khosla N; Kalaitzidis R; Bakris GL
Am J Nephrol; 2009; 30(5):418-24. PubMed ID: 19738369
[TBL] [Abstract][Full Text] [Related]
8. Moderate dietary salt restriction improves blood pressure and mental well-being in patients with primary aldosteronism: The salt CONNtrol trial.
Schneider H; Sarkis AL; Sturm L; Britz V; Lechner A; Potzel AL; Müller LM; Heinrich DA; Künzel H; Nowotny HF; Seiter TM; Kunz S; Bidlingmaier M; Reincke M; Adolf C
J Intern Med; 2023 Jul; 294(1):47-57. PubMed ID: 36945842
[TBL] [Abstract][Full Text] [Related]
9. Effect of longer-term modest salt reduction on blood pressure.
He FJ; Li J; Macgregor GA
Cochrane Database Syst Rev; 2013 Apr; (4):CD004937. PubMed ID: 23633321
[TBL] [Abstract][Full Text] [Related]
10. Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism.
Pecori A; Buffolo F; Burrello J; Mengozzi G; Rumbolo F; Avataneo V; D'Avolio A; Rabbia F; Bertello C; Veglio F; Mulatero P; Monticone S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3655-e3664. PubMed ID: 33942084
[TBL] [Abstract][Full Text] [Related]
11. Primary aldosteronism in hypertensive patients: clinical implications and target therapy.
Papanastasiou L; Markou A; Pappa T; Gouli A; Tsounas P; Fountoulakis S; Kounadi T; Tsiama V; Dasou A; Gryparis A; Samara C; Zografos G; Kaltsas G; Chrousos G; Piaditis G
Eur J Clin Invest; 2014 Aug; 44(8):697-706. PubMed ID: 24909545
[TBL] [Abstract][Full Text] [Related]
12. Effects of mineralocorticoid receptor antagonists in patients with hypertension and diabetes mellitus: a systematic review and meta-analysis.
Takahashi S; Katada J; Daida H; Kitamura F; Yokoyama K
J Hum Hypertens; 2016 Sep; 30(9):534-42. PubMed ID: 26674759
[TBL] [Abstract][Full Text] [Related]
13. Idiopathic primary hyperaldosteronism: normalization of plasma aldosterone after one month withdrawal of long-term therapy with aldosterone-receptor antagonist potassium canrenoate.
Armanini D; Scaroni C; Mattarello MJ; Fiore C; Albiger N; Sartorato P
J Endocrinol Invest; 2005 Mar; 28(3):236-40. PubMed ID: 15952408
[TBL] [Abstract][Full Text] [Related]
14. Patients With Primary Aldosteronism Respond to Unilateral Adrenalectomy With Long-Term Reduction in Salt Intake.
Adolf C; Heinrich DA; Holler F; Lechner B; Nirschl N; Sturm L; Görge V; Riester A; Williams TA; Treitl M; Ladurner R; Beuschlein F; Reincke M
J Clin Endocrinol Metab; 2020 Mar; 105(3):e484-93. PubMed ID: 31702016
[TBL] [Abstract][Full Text] [Related]
15. [Diagnosis and treatment outcome in primary aldosteronism based on a retrospective analysis of 187 cases].
Szücs N; Gláz E; Varga I; Tóth M; Kiss R; Patócs A; Jakab C; Perner F; Járay J; Horányi J; Dabasi G; Molnár F; Major L; Füto L; Rácz K; Tulassay Z
Orv Hetil; 2006 Jan; 147(2):51-9. PubMed ID: 16509213
[TBL] [Abstract][Full Text] [Related]
16. Preoperative mineralocorticoid receptor antagonist reduces postoperative hyperkalaemia in patients with Conn syndrome.
Zhang J; Libianto R; Lee JC; Grodski S; Shen J; Fuller PJ; Yang J
Clin Endocrinol (Oxf); 2022 Jan; 96(1):40-46. PubMed ID: 34743353
[TBL] [Abstract][Full Text] [Related]
17. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
[TBL] [Abstract][Full Text] [Related]
18. Renin as a Biomarker to Guide Medical Treatment in Primary Aldosteronism Patients. Findings from the SPAIN-ALDO Registry.
Parra Ramírez P; Martín Rojas-Marcos P; Paja Fano M; González-Boillos M; Pascual-Corrales E; García Cano AM; Ruiz-Sanchez JG; Vicente Delgado A; Gómez Hoyos E; Ferreira R; García Sanz I; Recasens Sala M; Barahona San Millan R; Picón César MJ; Díaz Guardiola P; Perdomo CM; Manjón-Miguélez L; Rebollo Román Á; Robles Lázaro C; Morales-Ruiz M; Calatayud M; Andree Furio Collao S; Meneses D; Sampedro-Nuñez MA; Mena Ribas E; Sanmartín Sánchez A; Gonzalvo Diaz C; Lamas C; Guerrero-Vázquez R; Del Castillo Tous M; Serrano Gotarredona J; Michalopoulou Alevras T; Tenés Rodrigo S; Roa Chamorro R; Jaen Aguila F; Moya Mateo EM; Hanzu FA; Araujo-Castro M
High Blood Press Cardiovasc Prev; 2024 Jan; 31(1):43-53. PubMed ID: 38225508
[TBL] [Abstract][Full Text] [Related]
19. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
[TBL] [Abstract][Full Text] [Related]
20. Real-World Effectiveness of Mineralocorticoid Receptor Antagonists in Primary Aldosteronism.
Tezuka Y; Turcu AF
Front Endocrinol (Lausanne); 2021; 12():625457. PubMed ID: 33841329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
